June 2017 DMID Council-Approved Concepts
Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
NB: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
- Centers of Excellence for Translational Research
- Partnerships for Countermeasures Against Select Pathogens
- Repurposing Target-Based Pharmaceutical Libraries for Discovery of Therapeutics Against Eukaryotic Pathogens
- Maintenance, Housing, and Research Support of Non-Human Primate Colonies and Cohorts for the Vaccine Research Center
For the published request for applications, see the November 30, 2017 Guide announcement, Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed).
For the published request for applications, see the August 21, 2017 Guide announcement, Partnerships for Countermeasures Against Select Pathogens (R01).
Repurposing Target-Based Pharmaceutical Libraries for Discovery of Therapeutics Against Eukaryotic Pathogens
For the published request for applications, see the September 12, 2017 Guide annoucement, Repurposing Target-Based Pharmaceutical Libraries for Discovery of Therapeutics against Eukaryotic Pathogens (R21/R33).
Maintenance, Housing, and Research Support of Non-Human Primate Colonies and Cohorts for the Vaccine Research Center
Request for Proposals—proposed FY 2019 initiative
Contact: Patrick Wilson
Objective: To have the capacity to expeditiously conduct collaborative preclinical research.
Description: The mission of the NIH, NIAID, Vaccine Research Center (VRC) is to conduct research to facilitate developing effective vaccines to elicit humoral and/or cellular immune responses to prevent human diseases. To fulfill this mission, the VRC must have the capacity to expeditiously conduct collaborative preclinical research which is facilitated by VRC’s Translational Research Program (TRP). The TRP serves three major functions at the VRC: 1) provides centralized support and service for all in vivo research conducted at the VRC, 2) conducts collaborative research and animal model development, and 3) operates a fully accredited lab animal facility. This initiative intends to provide the acquisition and research support for the entire Non-Human Primate program.
Through this initiative, VRC’s TRP will be able to respond to demands for non-human primate (NHP) research protocols toward the development of vaccines, including immunotherapeutics (e.g., broadly neutralizing antibodies and passive transfer), for emerging and re-emerging infectious diseases and to enable collaboration with researchers. The primary species required by the VRC is Specific Pathogen Free (SPF), Indian-origin, rhesus macaques; however, other species such as cynomolgus macaques, marmosets, or other NHP species may be required as approved by the VRC Animal Care and Use Committee (ACUC).
Through this initiative, the following support will be provided for VRC’s TRP:
- Site selection for research facility
- Acquisition and colony management
- Transportation of NHPs to research facility
- Animal Biosafety Level (ABSL) 2, ABSL3, and ABSL4 collaborative research protocols
- Study specimen collection, testing, and management
- Health monitoring and SPF surveillance
- Electronic data management
- Regulatory support and study coordination
Support services provided under this initiative allow VRC’s TRP to conduct basic and translational research through NHP research protocols. Support services may include the acquisition of NHPs, qualified personnel, materials, equipment, and facilities not otherwise provided by the government, necessary to perform the work. The required work may include purchasing, acquiring, transporting, establishing, and maintaining NHP research cohorts using select offspring or government-owned NHPs for VRC ACUC-approved experimental protocols. The nature of investigations conducted by VRC scientists involve the use of BSL2, BSL3, and possibly BSL4 infectious agents (e.g., simian immunodeficiency viruses and Ebola virus) and require long-term, overlapping, labor-intensive studies that will require animals to be maintained on study protocols for longer than 12 months post-inoculation. Procedures will be conducted in accordance with individual protocols issued under VRC or NIAID ACUC-approved Animal Study Proposals.
Through this initiative, VRC’s TRP will be able to rapidly begin in vivo testing of novel vaccine candidates and immunotherapeutics in NHPs using new and/or proven vaccine/therapeutic strategies.